313 related articles for article (PubMed ID: 28063190)
21. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype.
Masetti R; Pigazzi M; Togni M; Astolfi A; Indio V; Manara E; Casadio R; Pession A; Basso G; Locatelli F
Blood; 2013 Apr; 121(17):3469-72. PubMed ID: 23407549
[TBL] [Abstract][Full Text] [Related]
22. Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.
Hara Y; Shiba N; Yamato G; Ohki K; Tabuchi K; Sotomatsu M; Tomizawa D; Kinoshita A; Arakawa H; Saito AM; Kiyokawa N; Tawa A; Horibe K; Taga T; Adachi S; Taki T; Hayashi Y
Br J Haematol; 2020 Feb; 188(4):528-539. PubMed ID: 31612466
[TBL] [Abstract][Full Text] [Related]
23. ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.
Thirant C; Ignacimouttou C; Lopez CK; Diop M; Le Mouël L; Thiollier C; Siret A; Dessen P; Aid Z; Rivière J; Rameau P; Lefebvre C; Khaled M; Leverger G; Ballerini P; Petit A; Raslova H; Carmichael CL; Kile BT; Soler E; Crispino JD; Wichmann C; Pflumio F; Schwaller J; Vainchenker W; Lobry C; Droin N; Bernard OA; Malinge S; Mercher T
Cancer Cell; 2017 Mar; 31(3):452-465. PubMed ID: 28292442
[TBL] [Abstract][Full Text] [Related]
24. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.
Thiollier C; Lopez CK; Gerby B; Ignacimouttou C; Poglio S; Duffourd Y; Guégan J; Rivera-Munoz P; Bluteau O; Mabialah V; Diop M; Wen Q; Petit A; Bauchet AL; Reinhardt D; Bornhauser B; Gautheret D; Lecluse Y; Landman-Parker J; Radford I; Vainchenker W; Dastugue N; de Botton S; Dessen P; Bourquin JP; Crispino JD; Ballerini P; Bernard OA; Pflumio F; Mercher T
J Exp Med; 2012 Oct; 209(11):2017-31. PubMed ID: 23045605
[TBL] [Abstract][Full Text] [Related]
25. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.
Gress V; Roussy M; Boulianne L; Bilodeau M; Cardin S; El-Hachem N; Lisi V; Khakipoor B; Rouette A; Farah A; Théret L; Aubert L; Fatima F; Audemard É; Thibault P; Bonneil É; Chagraoui J; Laramée L; Gendron P; Jouan L; Jammali S; Paré B; Simpson SM; Tran TH; Duval M; Teira P; Bittencourt H; Santiago R; Barabé F; Sauvageau G; Smith MA; Hébert J; Roux PP; Gruber TA; Lavallée VP; Wilhelm BT; Cellot S
Blood Adv; 2024 Jan; 8(1):112-129. PubMed ID: 37729615
[TBL] [Abstract][Full Text] [Related]
26. Detection of RBM15-MKL1 fusion was useful for diagnosis and monitoring of minimal residual disease in infant acute megakaryoblastic leukemia.
Takeda A; Shimada A; Hamamoto K; Yoshino S; Nagai T; Fujii Y; Yamada M; Nakamura Y; Watanabe T; Watanabe Y; Yamamoto Y; Sakakibara K; Oda M; Morishima T
Acta Med Okayama; 2014; 68(2):119-23. PubMed ID: 24743787
[TBL] [Abstract][Full Text] [Related]
27. CBFA2T3-GLIS2-positive acute megakaryoblastic leukemia in a patient with Down syndrome.
Amano K; Takasugi N; Kubota Y; Mitani Y; Sekiguchi M; Watanabe K; Fujimura J; Oka A; Takita J; Hiwatari M
Pediatr Blood Cancer; 2020 Feb; 67(2):e28055. PubMed ID: 31736254
[No Abstract] [Full Text] [Related]
28. Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial.
Schweitzer J; Zimmermann M; Rasche M; von Neuhoff C; Creutzig U; Dworzak M; Reinhardt D; Klusmann JH
Ann Hematol; 2015 Aug; 94(8):1327-36. PubMed ID: 25913479
[TBL] [Abstract][Full Text] [Related]
29. Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic Leukemia Without Down Syndrome: A Retrospective Study in China.
Wang Y; Lu A; Jia Y; Zuo Y; Zhang L
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e301-e308. PubMed ID: 33257285
[TBL] [Abstract][Full Text] [Related]
30. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
[TBL] [Abstract][Full Text] [Related]
31. CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript.
Zangrando A; Cavagnero F; Scarparo P; Varotto E; Francescato S; Tregnago C; Cuccurullo R; Fagioli F; Nigro LL; Masetti R; Putti MC; Rizzari C; Santoro N; Pession A; Pigazzi M; Locatelli F; Basso G; Buldini B
Cytometry A; 2021 Aug; 99(8):844-850. PubMed ID: 33811445
[TBL] [Abstract][Full Text] [Related]
32. New hPSC-based human models to study pediatric Acute Megakaryoblastic Leukemia harboring the fusion oncogene RBM15-MKL1.
Ayllón V; Vogel-González M; González-Pozas F; Domingo-Reinés J; Montes R; Morales-Cacho L; Ramos-Mejía V
Stem Cell Res; 2017 Mar; 19():1-5. PubMed ID: 28412998
[TBL] [Abstract][Full Text] [Related]
33. A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1.
Mitsui-Sekinaka K; Sekinaka Y; Ogura Y; Honda M; Ohyama R; Oyama C; Isobe K; Mori M; Arakawa Y; Koh K; Hanada R; Nonoyama S; Kawaguchi H
Leuk Lymphoma; 2018 Jun; 59(6):1511-1513. PubMed ID: 29043865
[No Abstract] [Full Text] [Related]
34. Acute megakaryoblastic leukemia with a four-way variant translocation originating the RBM15-MKL1 fusion gene.
Torres L; Lisboa S; Vieira J; Cerveira N; Santos J; Pinheiro M; Correia C; Bizarro S; Almeida M; Teixeira MR
Pediatr Blood Cancer; 2011 May; 56(5):846-9. PubMed ID: 21370421
[TBL] [Abstract][Full Text] [Related]
35. AMKL chimeric transcription factors are potent inducers of leukemia.
Dang J; Nance S; Ma J; Cheng J; Walsh MP; Vogel P; Easton J; Song G; Rusch M; Gedman AL; Koss C; Downing JR; Gruber TA
Leukemia; 2017 Oct; 31(10):2228-2234. PubMed ID: 28174417
[TBL] [Abstract][Full Text] [Related]
36. Revealing the intratumoral heterogeneity of non-DS acute megakaryoblastic leukemia in single-cell resolution.
Su N; Li Z; Yang J; Fu Y; Zhu X; Miao H; Yu Y; Jiang W; Le J; Qian X; Wang H; Qian M; Zhai X
Front Oncol; 2022; 12():915833. PubMed ID: 36003795
[TBL] [Abstract][Full Text] [Related]
37. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.
Kudo K; Hama A; Kojima S; Ishii R; Morimoto A; Bessho F; Sunami S; Kobayashi N; Kinoshita A; Okimoto Y; Tawa A; Tsukimoto I
Int J Hematol; 2010 May; 91(4):630-5. PubMed ID: 20237876
[TBL] [Abstract][Full Text] [Related]
38. A case of
Forlenza CJ; Zhang Y; Yao J; Benayed R; Steinherz P; Ramaswamy K; Kessel R; Roshal M; Shukla N
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30455225
[TBL] [Abstract][Full Text] [Related]
39. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
[TBL] [Abstract][Full Text] [Related]
40.
de Matos RRC; Ferreira GM; Bonecker S; Rouxinol M; da Costa ES; Mello FV; Abdelhay E; Ribeiro RC; Zalcberg I; Silva MLM
Leuk Lymphoma; 2023 Dec; 64(12):2042-2046. PubMed ID: 37548333
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
